Demant A/S : Strong organic growth continues – 2024 guidance implies some upside
>Q4 review - Demant’s Q4 revenues of DKK 5,885m (+10.1% y-o-y, in line with expectations) were driven by strong organic growth of 10% (ODDO BHF/consensus 8%/10%). Hearing healthcare was up 12% organically, driven by an increase of 16% at Hearing aids, while Hearing care and Diagnostics were up 8%, respectively. Communication declined by 25% organically. H2 EBIT of DKK 2,134m (+31.8% y-o-y, margin 18.9%) was -6%/-1% below expectations. EPS of DKK 5.81 was a miss of exp...William Demant Holding is a holding company. Through its subsidiaries, Co develops, manufactures and sells products and equipment designed to aid the hearing and communication of individuals. Co. focuses on four areas: Hearing Devices, Diagnostic Instruments, Hearing Implants and Personal Communication. Co.'s hearing devices include Oticon, Bernafon, Sonic, Phonic Ear, and FrontRow. Co.'s Hearing implant consist of Oticon Medical. Co.'s diagnostic instruments include Maico, Interacoustics, Amplivox, Grason-Stadler, MedRx, and Micromedical. Co.'s personal communication consists of Sennheiser Communications.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.